This patent is a novel way to expand bone marrow cells ex vivo through contacting the bone marrow with a family of compounds. The single issued independent claim covers "A method for the transplantation of bone marrow cells" and the method involved contacting with a specific family of compounds. The first dependent claim states one member of this family of compounds as being...
Bryostatin is a drug derived from a type of symbiont bacteria. Although bryostatin has been used in clinical trials for oncology, results have not been excellent. This patent teaches that bryostatin and various derivatives thereof are useful for stimulation of hematopoietic stem cell proliferation. It will be interesting to see if bryostatin works on stimulating stem cell activity of...
This patent covers the composition of matter for several compounds and family of compounds that increase hematopoiesis. The compounds which are oxpurine nucleosides and their congeners, and acyl derivatives are demonstrated to accelerate hematopoietic reconstitution in both chemotherapy and irradiation induced suppression mouse models. In total the patent has over 70 examples. The...
Small molecules are provided that stimulate hematopoietic stem cell proliferation. These molecules may be of interest for stimulation of non-hematopoietic stem cells.
This patent teaches the use of IL-7 for stimulation of hematopoiesis, as well as increasing the output of lymphocytes. IL-7 has several interesting properties, including the ability to support homeostatic expansion of T cells.
This patent covers the use of IL-7 to stimulate hematopoiesis.
This patent covers a specific DNA enhancer sequence that is activated uniquely in embryonic stem cells. Such an enhancer is useful for numerous genetic engineering techniques, as well as, I believe, for generation of transgenic animals.
G-CSF is used clinically for stimulation of neutrophil production in pateints that have taken chemotherapy, radiation therapy (in some cases), as well as post bone marrow tranplant. This patent covers peptide derivatives of G-CSF that are useful for stimulation of hematopoiesis. It may be interesting to use this patent to compete with currently used G-CSF formulations.
This invention covers the synthethized form of a tetrapeptide that inhibits bone marrow stem cell entery into cell cycle. The original inhibitory activity was derived from fetal calf bone marrow as a biological "soup" but in this patent synthesis and structure are revealed. The use of agents that inhibit stem cell entry into cell cycle could occur when chemotherapy or radiation is...
This patent is broad reaching in that it covers the ex vivo expansion of bone marrow for treating a pateint whose bone marrow has been comprised. Essentially, this patent was ahead of its time since numerous companies are trying to perform this process even today. Essentially the patent's since independent claim covers extraction of bone marrow, ex vivo replication so that hematopoietic...